Pruebas moleculares para la detección de SARS-CoV-2

José Enrique Oliva Menacho

Texto completo:

HTML PDF XML

Resumen

Introducción: Los coronavirus generan enfermedades respiratorias, hepáticas o neurológicas, con gravedad variable en su huésped. La reacción en cadena de la polimerasa con transcriptasa inversa en tiempo real es la metodología de referencia para confirmar la detección del virus SARS-CoV-2. Se realizó una revisión bibliográfica en el periodo de julio a noviembre de 2021, en los recursos disponibles en MEDLINE, SciELO, Pubmed y Elsevier. Del total de consultas se citaron 34 referencias.
Objetivo: Describir las pruebas moleculares para la detección de SARS-CoV-2.
Desarrollo: Se han diseñado tres tipos de ensayos de rRT-PCR, para la detección de SARS-CoV-2. Las pruebas descritas son específicas para genes ARN (polymerase dependent RNA - RdRp), genes E (upE) y genes Nnes (N). Los Centros para la Prevención y Control de Enfermedades (CDC) de los EE.UU., han desarrollado la rRT-PCR dirigidos a la proteína N de la nucleocápside del material genético SARS-CoV-2, los ensayos genes E (upE) y gen de la proteína 1b (ORF 1b) se pueden complementar para la detección y confirmación.
Conclusiones: Las dianas que se emplean para la detección específica del genoma del SARS-CoV-2 por RT-PCR en tiempo real, se encuentran en las regiones ORF1a y 1b, RdRp, N, S y E del ARN viral.

Palabras clave

COVID-19; pruebas moleculares; RT PCR; secuenciación.

Referencias

De Groot RJ, Baker SC, Baric RS, Enjuanes L, Gorbalenya AE, Holmes KV, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J Virol. 2013;87(14):7790-2.DOI:10.1128/JVI.01244-13

Gloza-Rausch F, Ipsen A, Seebens A, Göttsche M, Panning M, Drexler JF, et al. Detection and prevalence patterns of group I coronaviruses in bats, northern Germany. Emerg Infect Dis. 2008;14(4):626-31. DOI: 10.3201/eid1404.071439

Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med. 1966;121(1):190-3. DOI: 10.3181/00379727-121-30734

Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1967-76. DOI: 10.1056/NEJMoa030747

Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci USA. 2004;101(16):6212-6. DOI: 10.1073/pnas.0400762101

Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol. 2005; 79(2):884-95. DOI: 10.1128/JVI.79.2.884-895.2005

Zlateva KT, Coenjaerts FE, Crusio KM, Lammens C, Leus F, Viveen M. No novel coronaviruses identified in a large collection of human nasopharyngeal specimens using family-wide CODEHOP-based primers. Archives of Virology. 2013;158(1):251-5. DOI: 10.1007/s00705-012-1487-4

Lan L, Dan X, Guangming Y. Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA. 2020;323(15):1502-03. DOI:10.1001/jama.2020.2783

Peng W, Xinxin H, Eric H Y, Jessica Y, Kathy S, Joseph T, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China. Euro Surveill Bull. 2020;25(3):pii=2000044. DOI: 10.2807/1560-7917.ES.2020.25.3.2000044

Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020;323(8):707-8. DOI:10.1001/jama.2020.0757

Cuadra TE, Guadrón Meléndez AA, Cruz Aguilar R de J, Vásquez Rodriguez EA. Factores relevantes sobre el ensayo RT-PCR para la detección de SARS-CoV-2, virus causante del COVID-19. Alerta.2021;4(1): 31-9. DOI:10.5377/alerta.v4i1.10060

Palm D, Pereyaslov D, Vaz J, Broberg E, Zeller H, Gross D, et al.Laboratory capability for molecular detection and confirmation of novel coronavirus in Europe, November 2012. Euro Surveill. 2012;17(49):20335. DOI: 10.2807/ese.17.49.20335-een

Van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio. 2012;3(6): e00473-12. DOI: 10.1128/mBio.00473-12

Timothy M, Bernstein H, Bradley J, Englund J, File T, Gravenstein S, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clinical Infectious Diseases. 2019; 68 (6): 1-47. DOI: 10.1093/cid/ciy866

Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. 2012;17(39): 20285. DOI: https://DOI.org/10.2807/ese.17.39.20285-en

Herzog P, Drosten C, Müller M. Plaque assay for human coronavirus NL63 using human colon carcinoma cells. Virol J. 2008;5(1):138-142. DOI: https://DOI.org/10.1186/1743-422X-5-138

Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, Doerr HW. Stability and inactivation of SARS coronavirus. Med Microbiol Immunol. 2005;194(1-2):1-6. DOI: 10.1007/s00430-004-0219-0

Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. Front. Microbiol. 2019; 10:1781. DOI: 10.3389/fmicb.2019.01781

Liu R, Han H, Liu F, Lv Z, Wu K, Liu Y, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim Acta. 2020; 505: 172-5. DOI: 10.1016/j.cca.2020.03.009

Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu D, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3):2000045. DOI: 10.2807/1560-7917.ES.2020.25.3.2000045

Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for laboratory confirmation of Novel human Coronavirus (hCoV-EMC) Infections. Euro Surveill. 2012; 17(49): 20334. DOI: 10.2807/ese.17.49.20334-en

Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020; 58(7):1070-1076. DOI: 10.1515/cclm-2020-0285

Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID19) in China: a report of 1014 cases. Radiology. 2020; 96(2): 32-40. DOI: 10.1148/radiol.2020200642

Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020; 126: 108961. DOI: 10.1016/j.ejrad.2020.108961

Shen Z, Xiao Y, Kang L, Ma W, Shi L, Zhang L, et al. Genomic diversity of SARS-CoV-2 in coronavirus disease 2019 patients. Clin Infect Dis. 2020; 71(15):713-720. DOI:10.1093/cid/ciaa203

Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020; 20(7):816-26. DOI: 10.1016/S1473-3099(20)30160-2

Pan American Health Organization / World Health Organization. Epidemiological Update: Novel Coronavirus (2019 nCoV) 20 January 2020. Washington, D.C.: PAHO/WHO; 2020.[acceso: 03/03/2020]. Disponible en: https://iris.paho.org/handle/10665.2/51851

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395(10223): e30-e31. DOI: 10.1016/S0140-6736(20)30304-4

Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. Med (NY). 2020;1(1):105-113.e4. DOI: 10.1016/j.medj.2020.04.001

Pitts J, Li J, Perry J, Du Pont V, Riola N, Rodriguez L, et al. Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants. BioRxiv. 2022;1(1):1-46.DOI: 10.1101/2022.02.09.479840

Ionescu MI. An Overview of the Crystallized Structures of the SARS-CoV-2. Protein J. 2020; 39(6): 600-18.DOI: 10.1007/s10930-020-09933-w

Lisa M. IL-6 blockers tested against COVID-19. C&EN. 2020; 98(11):13-20. DOI: 10.1021/cen-09811-buscon3

Cision PR Newswire. Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800. Pensilvania: Inovio Pharmaceuticals; 2020.[acceso: 03/03/2020]. Disponible en: https://www.prnewswire.com/news-releases/inovio-accelerates-timeline-for-covid-19-dna-vaccine-ino-4800-301015031.html

HusseyC. Moderna ships mRNA vaccine against novel coronavirus (mRNA-1273) for phase 1 study. Cambridge, Mass: Business Wire; 2020.[acceso: 24/02/2020]. Disponible en: https://www.bloomberg.com/press-releases/2020-02-24/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273-for-phase-1-study

Enlaces refback

  • No hay ningún enlace refback.


URL de la licencia: https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es